<DOC>
	<DOCNO>NCT02631642</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability single dose HMPL-689 healthy volunteer To determine pharmacokinetic profile single oral dos HMPL-689 healthy volunteer</brief_summary>
	<brief_title>A Study HMPL-689 Healthy Volunteers</brief_title>
	<detailed_description>Subjects receive single dose HMPL-689 matching placebo Day 1 . The plan dose level : 1 , 2.5 , 5 , 10 , 20 , 25 30 mg ( 7 cohort 8 subject ) . In dose cohort , 8 subject randomize receive HMPL-689 ( 6 subject ) placebo ( 2 subject ) feed condition standard meal . For first dose Cohort ( 1 mg ) , sentinel group 2 subject ( 1 HMPL-689 1 placebo ) dose 24 hour prior plan dose remain six subject . The decision dose escalation study termination make jointly principal investigator sponsor base clinical data ( safety , tolerability , available PK data clinical laboratory value ) . Any dose level may repeat , reduce split 2 dos deem appropriate Principal Investigator Sponsor 's medical Expert .</detailed_description>
	<criteria>1 . Informed consent must obtain write subject enrollment study 2 . Healthy male subject age 18 45 year inclusive time screen 3 . Body mass index ≥19.0 ≤ 30.0 kg/m2 4 . Willing comply contraceptive requirement study must donate sperm study 3 month afterwards . Subjects must agree use condom abstain sexual intercourse throughout trial 30 day afterwards 1 . Family history premature Coronary Heart Disease 2 . History immunosuppression opportunistic infection receipt live virus vaccination within 3 month prior screen 3 . Clinically significant abnormality determine medical history physical examination , laboratory test , especially liver renal function 4 . Clinically significant finding ECG , blood pressure heart rate , determine Clinical Investigator 5 . Subjects risk tuberculosis ( TB ) , define : 1 . Current clinical laboratory evidence active TB 2 . History TB 3 . A positive QuantiFERON® test screening within 6 month prior Day 1 6 . Any medical condition require regular use medication 7 . Exposure prescription medication within 30 day prior Day 1 8 . Exposure medication , include overthecounter medication , herbal remedy vitamins 14 day prior first dose ( except paracetamol ) 9 . Participation another clinical trial investigational drug within 30 day Day 1 10 . Treatment previous 3 month drug know welldefined potential toxicity major organ 11 . Current smoker 10 cigarette equivalent/ day prior commence study unable completely stop smoking study 12 . Symptoms clinically significant illness 3 month study 13 . Presence sequelae gastrointestinal , liver kidney disease , condition know interfere absorption , distribution , metabolism , excretion drug 14 . Chronic constipation diarrhea , irritable bowel syndrome , inflammatory bowel disease , hemorrhoids anal disease regular recent presence blood feces 15 . History significant allergic disease ( e.g . allergic medication ) acute phase allergic rhinitis previous 2 week randomization/ enrollment food allergy 16 . Clinically significant history liver disease , include cirrhosis , current alcohol abuse , current know active infection HIV , hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) 17 . Current evidence drug abuse history drug abuse within one year randomization/ enrollment 18 . Mental condition render subject incapable understand nature , scope , possible consequence study 19 . Unlikely comply clinical study protocol ; e.g . uncooperative attitude , inability return followup visit , improbability complete study 20 . Subject investigator subinvestigator , research assistant , pharmacist , study coordinator , staff relative thereof directly involve conduct protocol</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>